← Autonomix Medical, Inc. Common Stock overview

Autonomix Medical, Inc. Common Stock vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Autonomix Medical, Inc. Common Stock (AMIX)

Q3 2026
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

August 2026
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

Latest
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 2026
▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

  • First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.

    This is the core new event that directly explains the profit surge and its cause.

  • Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.

    It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.

  • Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.

    It shows the market's cumulative response to the profit news, indicating sustained upward momentum.

  • Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.

    It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 2026
▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

  • First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.

    This is the core new event that directly explains the profit surge and its cause.

  • Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.

    It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.

  • Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.

    It shows the market's cumulative response to the profit news, indicating sustained upward momentum.

  • Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.

    It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest
▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

  • First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.

    This is the core new event that directly explains the profit surge and its cause.

  • Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.

    It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.

  • Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.

    It shows the market's cumulative response to the profit news, indicating sustained upward momentum.

  • Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.

    It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.